An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis

14/07/2026
14/07/2026
EU PAS number:
EUPAS1000001029
Study
Ongoing
Subscribe
Download as PDF
Study summary
No information provided.
Study identification

EU PAS number

EUPAS1000001029

Study ID

1000001029

Official title and acronym

An Observational Registry of Abatacept in Patients with Juvenile Idiopathic Arthritis

DARWIN EU® study

No

Study countries

Austria
Belgium
Brazil
Canada
Denmark
France
Germany
Greece
Hungary
Israel
Italy
Latvia
Mexico
Netherlands
Norway
Peru
Portugal
Puerto Rico
Romania
Russian Federation
Saudi Arabia
Slovakia
South Africa
Spain
United Kingdom
United States

Study description

The purpose of this study is to describe the long-term safety of abatacept treatment for juvenile idiopathic arthritis (JIA) by quantifying the incidence rates of serious infections, autoimmune disorders, and malignancies.

Study status

Ongoing
Research institutions and networks

Institutions

Networks

Paediatric Rheumatology International Trials Organisation (PRINTO)
Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Ireland
Italy
Latvia
Lithuania
Luxembourg
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
Switzerland
United Kingdom
First published:
06/10/2022
Network
ENCePP partner
Pediatric Rheumatology Collaborative Study Group (PRCSG)

Contact details

Robert Carroll

Primary lead investigator

Study timelines

Date when funding contract was signed

Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Bristol-Myers Squibb
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

EU RMP category 3 (required)